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that a broader andmulti-faceted conceptualization of utility and valuewould enrich the ethical and social discus-
sion of DTC testing in several ways: First, looking atways inwhichDTC testing can have personal and social value
for users – in the form of entertainment, learning, or a way to relate to others – can help to explain why people
still take DTC tests, and will, further down the line, foster a more nuanced understanding of secondary and ter-
tiary uses of DTC test results (which could verywell unearth newethical and regulatory challenges). Second, con-
sidering the economic value and broader utility of DTC testing foregroundswider social and political aspects than
have been dominant in the ethical and regulatory debates surrounding DTC genetics so far. These wider political
aspects include theprofound power asymmetries that characterize the collection and use of personal genetic data
in many contexts.
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Internet-based companies offering genetic testing services directly
to consumers have been surrounded by controversy from the start.
While some authors have celebrated the arrival of genome-wide tests
on the onlinemarket asmarking a revolution in patient empowerment,
others have raised concerns about consumers receiving genetic risk
information without medical advice. The main concerns have focused
on the negative psychological effects that genetic or genomic risk-
susceptibility data with low predictive value could have on test-takers
(e.g. by causing stress or anxiety), the potential adverse impact of
these tests on the broader healthcare services in terms of unnecessary
requests for screening and diagnostic services, and the possible privacy
violations of sensitive and personal data (for an overview, see Caulﬁeld
andMcGuire, 2012). Risks are seen as particularly high for people with-
out adequate genetic literacy (Ofﬁt, 2008; McGuire and Burke, 2008;
Leighton et al., 2012).
Moreover, some social scientists and ethicists consider direct-to-
consumer (DTC) genetics as the epitome of a particularly individualist
or consumerist approach to healthcare (e.g., Hunter et al., 2008;
McGuire and Burke, 2008; Harvey, 2010). Donna Dickenson recentlyrrini),
. This is an open access article underreferred to DTC genetic tests as one of the most problematic instantia-
tions of personalized medicine — a new model of healthcare directly
linked to the private sector and dictated by narcissism and the ideal of
personal choice (Dickenson, 2013).
In the context of health, the DTC genetics market has not, as some
enthusiasts had predicted, become a large and lucrative industry. The
DTC genetics market continues to be dominated by genetic ancestry
testing; health-related testing forms a very small niche within this mar-
ket (Wright and Gregory-Jones, 2010; Petrone, 2014). But contrary to
some predictions, health-related DTC testing has not disappeared either.
One of the pioneers of human genome-wide tests, the California-based
company 23andMe, celebrated its one-millionth customer last year.
“Just ﬁfty years ago”, an e-mail sent out to customers in June 2015
read, “doctors were reluctant to tell their patients if they had cancer.
Theworld is different today”.1 (Note, however, that the ﬁgure of onemil-
lion includes customers who bought the test purely out of interest in
their genetic ancestry; it also includes some number of people—perhaps
many thousands—who received 23andMe's service for free). Moreover,
new DTC testing services are emerging, such as personal microbiome
analysis, offering users a genetic analysis of, for example, their gut bacte-
ria. Providers of such services include both for-proﬁt (uBiome.com) and
non-proﬁt (American Gut Project, British Gut Projects) organizations,1 E-mail received by one of the authors (BP), customer #54,472.
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of microbial gut data.2
In recent years, a number of empirical studies have investigated the
motivations, attitudes, and experiences of the general public and actual
users of DTC tests. Findings from these studies paint a rather complex
and partly contradictory picture (for a recent systematic overview of
this literature, see Covolo et al., 2015). The main reasons for favorable
attitudes towards these tests both among actual users and members
of the public who had not taken a test have been their presumed med-
ical importance and thepotential for this information to prompt users to
adopt a healthier lifestyle (McBride et al., 2009; Bloss et al., 2010;
Cherkas et al., 2010; McGuire et al., 2009; Su et al., 2011; Savard et al.,
2014). At the same time, both qualitative and quantitative studies of ac-
tual users of DTC genetics show no evidence for changes in anxiety
levels, psychological health, diet, exercise or use of screening tests
among DTC genetics users (Bloss et al., 2011, 2013; McGowan et al.,
2010). Despite the absence of evidence for health-related behavior
change, or psychological changes, however, most surveyed customers
of DTC tests have been satisﬁed with the test experience (Bloss et al.,
2010, 2011, 2013; McGowan et al., 2010).3 Why is this the case? If we
accept that DTC genetic tests have little or no clinical utility – under-
stood, in the narrow sense of the word, as the ability of a test to prevent
or ameliorate adverse health outcomes such as mortality, morbidity, or
disability through the adoption of efﬁcacious treatments conditioned on
test results (Grosse and Khoury, 2006; see also Khoury, 2003; Foster
et al., 2009) 4 –why do health-related DTC tests still exist?What utility
and value do these tests have for test-takers, and for other actors?
2. DTC testing: Utility beyond the clinic
Let usﬁrst take a look speciﬁcally atwhat empirical studies say about
why people take DTC tests. McGowan and colleagues interviewed early
adopters of genome-wide DTC testing; they found that the two most
common reasons for taking the test were to obtain health-related infor-
mation and to learn about genetic risk factors (McGowan et al., 2010,
269). Another important motivation – not surprising in the group that
this study focused on –was the desire to be on the vanguard of adopting
new technologies. Other studies that analyzed the complexity andwide
variety of practices around personalized genetic information showed2 These projects' websites strike a very different tone than DTC services that promise
personalized genetic risk proﬁles; theGut Projects' rhetoric revolvesmore aroundbuilding
a publicly accessible database to improve our understanding of the relationship between
health and gut bacteria. Rather than receiving risk proﬁles, users see graphic representa-
tions of how their gut bacteria compare to other people whose bacteria have been ana-
lyzed. Although it remains to be seen whether users take their results as an incentive to
eat healthier, more diverse diets, at this point, the question of what utility and value these
tests have is still entirely open.
3 The Scripps Genomic Health Initiative is the ﬁrst large-scale, longitudinal survey with
several thousand voluntary participants who purchased a genomewide DTC test at a
discounted rate from the former U.S.-based DTC company, Navigenics. The study sought
to understand the behavioral and psychosocial impact of these data. Participantswere sur-
veyed for the ﬁrst time when they decided to take the test, as well as three and twelve
months after receiving the results. Out of the 3600 respondents who answered the initial
survey, 1300 also completed both the three and twelvemonth follow-ups. The short-term
follow-up survey after three months showed no measurable changes in anxiety, psycho-
logical health, diet, exercise or use of screening tests among these actual personal geno-
mics users (Bloss et al., 2011). These ﬁndings contrast with those from hypothetical
users (see, e.g., McBride et al., 2009; Cherkas et al., 2010; McGuire et al., 2009) and chal-
lenge some of the main assumptions in the discussion of DTC genetics: Here, test-results
do not seem to have detrimentally affected test-takers; nor did results seem to have led
to positive lifestyle changes. The twelve-month follow-up survey corroborated the trend
found in results from the three-month survey and also indicated that customers felt rather
satisﬁed with the test results, despite the lack of behavioral changes (Bloss et al., 2013).
4 There is no universally accepted deﬁnition of clinical utility. Besides narrow deﬁni-
tions of the term that focus on the impact that an action has on concrete health outcomes,
other deﬁnitions of clinical utility comprise much wider ranges of usefulness, sometimes
even including societal value (for an excellent overview see Grosse and Khoury, 2006).
In this paperwe use the term “clinical utility” to refer to a test's ability to affect health out-
comes (via informing treatment choice, etc.), as we consider this the most speciﬁc deﬁni-
tion with the highest analytic value.that what users “get out of” DTC genetic testing has little, of any-
thing, to do with clinical decision making. Respondents in empirical
studies referred to the role of curiosity and fascination with techno-
logical innovations and genetics; interest in participating in biomed-
ical research (Su et al., 2011; Vayena et al., 2014); pride or
professional interest in being on the vanguard as early adopters of
a new technology (McGowan et al., 2010); interest in experimenting
with biosocial relationships or a more proactive patient-role
(Ducournau and Beaudevin, 2011; Ducournau et al., 2011); or the “fun
factor”: a broad concept which encompasses the satisfaction of either
taking part in promising and potentially useful research, or being part
of a “cool” innovation (Vayena et al., 2012).
In all of these surveys it is difﬁcult to distinguish between motiva-
tions to take a DTC test and the utility/value that DTC testing has for
users. This is because when people are asked after having taken the
test onwhy they took the test in the ﬁrst place, there is noway of ascer-
taining on how they themselves separate motivations from utility; in
light of the narrative structure of autobiographical memories it seems
likely that in recalling motivations/expectations and ex-post utility of
PGT, these notions of testing shade into one another.5
Both in terms of reportedmotivations to undergo testing and report-
ed uses and thoughts about test results, another distinction that cannot
easily be upheld is that between the personal and social domains. In a
study carried out with volunteers in the British Twins cohort, for
example, roughly 80% of those who said they were interested in taking
a DTC test (5%–50% depending on the price of the service) said they
wanted to do so to be able to convey risk information to their children
(Cherkas et al., 2010). It is impossible, here, to describe such a
(hypothetical) use of DTC test results purely as either a “personal” or
“social” use — it is both. In studies with actual DTC genetics users, ﬁnd-
ings fromVayena et al.'s (2012) study in particular show the importance
of curiosity, entertainment and enjoyment for people when they use
test results to ﬁnd genetic relatives online or in conversations with
friends and family. In this survey of university students in Switzerland,
the potential contribution to biomedical research was listed as the most
importantmotivation for having these tests (Vayena et al., 2014). In addi-
tion, a qualitative study of online DTC test takers done in France found
that all respondents had visited the dedicated blogs and forum run by
the testing companies at least once. In some cases, they also used these
platforms to share their own personal genetic information and establish,
in the words of the authors, new forms of “biosociality” (Ducournau and
Beaudevin, 2011; Ducournau et al., 2011).
Such ﬁndings undermine the portrayal of DTC genetic test takers as
self-centered narcissists. The taking of DTC tests is typically not the so-
lipsistic activity of an individual person, but something that is done
with, or with reference to, family members, signiﬁcant others, friends,
or even society as a whole. In this sense, genomic information is person-
al and social at the same time: it is personal, but formore than one person
(Laurie, 2001; Taylor, 2012;Widdows, 2013; Prainsack, in preparation).
Reading one's “personalized” health report can be an entertaining and
interesting activity that does not serve the purpose of obtaining action-
able health information or exploring one's genomic self, but it also can be
used to socialize on or ofﬂine, or to share data and information for social,
research or philanthropic purposes.
Another possible use of personal genomic information obtained
from DTC tests is the process of identity making. This aspect has been
widely discussed within social science scholarship on DTC genetics
(for an overview see Fishman and McGowan, 2014). In the early days of
online genome-wide tests, journalists, biologists and other early adopters
reported their experiences as genetic test-takers in the press, academic
journals, and books (e.g., Duncan, 2009; Pinker, 2009; Angrist, 2010;5 In fact, the Scripps Genomic Initiative was a longitudinal study that included an inter-
view before the test and two follow-ups. However, the questionnaire collected information
basically about users' concerns and not theirmotivations of undergoing susceptibility genet-
ic tests (Bloss et al., 2010, 2011, 2013).
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enjoyed exhibiting and speaking about their genomic selves. Genomic in-
formation has been used to construct “auto-biologies”, i.e., narrative de-
scriptions of one's own identity based on biological data (Harris et al.,
2015). Some people have published videos on YouTube, reporting their
results, but also document the process itself, often ﬁlming themselves
going through the different steps of the procedure, from spitting into a
test tube to the impact of the ﬁrst sight of the report, to interpreting the
report and some of their ideas and feelings about it (Harris et al., 2014,
in press). Other users have blogged about their test results on social net-
works, or used apps to visualize their results on mobile phones to show
them to others. Genetic or genomic data can serve as a starting point to
tell a story about ourselves, claim a place in the ongoing evolution of bio-
medicine, or contribute to medical research. Here it becomes apparent
that the process of personal identity making is inherently relational;
when genomic data are used to explore or reiterate one's identity, these
activities simultaneously build, change, and reinforce relations to others
(see also Dheensa et al., 2015). These others can be family members,
friends, or members of the same cultural or ethnic group, but they can
also be society as a whole, e.g., when people make their data accessible
for use in disease research. In some instances these explorations can
have unintended consequences (e.g. Hughes, 2013; Doe, 2014).
Last but not least, another kind of utility that DTC testing can have is
that people can use personal genomic information to do something that
they consider good for others, or for society as a whole. They can estab-
lish or reinforce their identity as somebody who cares about others and
practices solidarity by making their test results available to medical
research via non-proﬁt organizations such as openSNP (opensnp.org)
or Open Humans (openhumans.org). The willingness of many people
to use their genetic data in such a way is, however, also something
that for-proﬁt companies seek to harness for their own purposes.
23andMe, for example, makes strong use of the rhetoric of scientiﬁc de-
mocratization to enroll users as research participants willing to “share”
not only their genomic data, but also their personal, and possibly famil-
ial and clinical histories (Spector and Prainsack, 2013). Customers are
asked to answer “quick questions”, which take nomore than a few sec-
onds to answer, or ﬁll in longer questionnaires about their physical
traits, clinical histories, biological, and/or psychological characteristics.
They can also participate in special projects tailored to people affected
by speciﬁc diseases such as Parkinson's disease or sarcoma. The compa-
ny frames this as “joining the scientiﬁc revolution”.6 As we have argued
elsewhere, the practice of genome sharing also denotes a new form
of participation in an emerging model of healthcare based on self-
produced and self-administered biomedical data (Turrini, 2015;
Prainsack, 2014a).
By directly involving users in research projects, their personal
genomic and clinical information can become socially, scientiﬁcally, or
economically valuable. DTC genetics has also taken on the roles of
being a resource for biomedical research, a strategy for more participa-
tory approaches to healthcare, and a proﬁt-making scheme.3. The multiple values of genomes
Given the relatively small numbers of people worldwide who have
taken a DTC genetic test, the considerable attention that online personal
genetic testinghas received in themedia, in expert circles, and frompol-
icy makers, is somewhat puzzling (Wright and Gregory-Jones, 2010).
An important reason for this is that DTC genetic testing and genomic
testing do not ﬁt neatly into the categories that dominate regulatory
and discursive space (Prainsack, 2011; Wienroth and Rodrigues,
2015). This space presupposes not only a clear separation between
experts and patients, companies and consumers, and health-related
and non-health-related information, but also clinical and non-clinical6 https://www.23andme.com/en-eu/research/.utilities. Practices and entities that fall in between these categories are
thus problematic; for example, by excluding clinical professionals
from the disclosure of genetic risk information to consumers, or by
those consumers attaching value to DTC PG beyond predictive clinical
value.
The clear boundaries between these categories used in regulation
stand in stark contrast to the multiple goals that genomic information
serves. Personal genomics tests can deliver probabilistic information
about genetic predisposition to a disease, the presence of mutations
that can be passed to a person's offspring, the customization of nutrition
or physical training (although these tend to be poorly validated), aswell
as insight into parts of one's genetic ancestry. Clinical utility is not inher-
ent to the material of the DNA sequence, but is produced by humans in
conjunction with human-made artifacts, such as sequencing machines,
algorithms to calculate risk information, and visualization graphics
and decision aids. Far from being made of letters that can be read as a
text, as suggested by the metaphors dominating the early days of the
Human Genome Project, genomic information does not harbor intrinsic
clinical, social, or personalmeaning. Ironically, part of what personal ge-
nomics services – including some for-proﬁt companies – do is to work
with, and not against, this complexity, in order to exploit all the possible
uses that genetic datamay have. The initial resistance of DTC companies
such as deCODE, Pathway Genomics, and 23andMe (only the latter
is still in the DTC market) to clarify their position on the health-
relevance of the test results, has so far been framed primarily in terms
of entrepreneurial shrewdness or disingenuousness. But their resistance
to clarifying the health-relevance of their testing services might also re-
ﬂect the inherent uncertainty of most genetic information.
The concept of value is a good complement to utility in capturing the
manyways in which genomic data can be used in the complex process-
es of the production, interpretation, circulation, storage, and sharing of
genomic information. In economics, value is often used as something
that can be calculated precisely, while utility is something broader, not
precisely calculable, but subjective. In this paper, we use the term
“value” in a broader sense, namely to refer to a person's judgment that
something is important to her. This importance could be of a pecuniary,
emotional, identity-related, social, or any other nature. Value does not
refer only to social, scientiﬁc and political value but also the economic
sphere. Mapping the different kinds of value that personal genomic in-
formation holds in concrete contexts can help us see and address a
wider range of opportunities and issues related to the utilization of ge-
nomic information than is currently the case. By referring to the “utility”
of genomic information, in contrast, in this paper we refer to something
that has practical value, irrespective of the value that the person attri-
butes to it personally. This practical value could unfold in clinical
decision-making (clinical utility), in providing entertainment or plea-
sure or relating to others (personal and social utilities), or other realms
(see Foster et al., 2009).
DTC tests can have several layers of utility and value for test-takers
but also for other actors such as testing companies, commercial re-
searchers, and society as a whole. DTC tests can have educational and
personal utility in teaching the test taker – aswell as her friends or fam-
ily if they accompany her in this process – about the nature of genomic
information, including the ambiguities and limitations of it. For some
people the process will be pleasurable or entertaining, adding to the
personal value or utility (we do not, of course, mean to deny that the
testing process can elicit negative emotions; we do not discuss this
here, however, as this would not fall under utility or value). When
test-takers use aspects of the testing process, or the test results, to en-
gage with others or to articulate parts of their own identity, then DTC
testing has social utility or value aswell. If a person deposits genomic in-
formation in a repository or database used for scientiﬁc beneﬁt, then
this social utility or value can extend to the entire society, and it can,
at the same time, unfold personal value as well: In all of the qualitative
studies on actual users mentioned here, making somebody's personal
genetic or genomic data available to others was cited as a way to be
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broadly, “as a way to (be) part of something greater than (oneself)” (Su
et al., 2011, 141).
Last but certainly not least, for the providers of DTC testing, the data
and information that these tests yield can also have signiﬁcant ﬁnancial
utility and value. The term that is often used for making one's informa-
tion available to others, “sharing”, evokes the excitement for a new
glittering healthcare informed by genomics and the language of public
beneﬁt in commercial PG providers' discourse, and seems to combine
personal and social values with biomedical utility. Yet, the profound
limits of that biomedical utility thus far and the stark power asymmetry
between users and the organization providing the testing service – es-
pecially, but not only when it is a commercial company – complicates
any purely optimistic picture. In the case of 23andMe, for example, de-
spite the company's strong rhetoric around participation and democra-
tization, the degree to which the company is transparent to its users is
very different from the degree to which its users are transparent to
the company (Sterckx et al., 2013), and the inﬂuence that users have
on how the company will use their data is very limited (Prainsack,
2014a, 2014b). Moreover, the company's announcement in spring
2015 that it will enter the ﬁeld of drug development (Herper, 2015)
could be seen as indicating that the desire to make science more demo-
cratic and “open” has servedmostly as a strategy to grow its proprietary
database. The situation is different for non-proﬁt initiatives that seek to
encourage data-sharing for research for public beneﬁt and organize the
relationship with their users accordingly, i.e., work to make it more re-
ciprocal and in some cases even solidaristic (Prainsack and Buyx, 2013).
4. Conclusion: Moving power asymmetries to the center of the
ethical debate
Personal genomic data, even those related to health, are used for a
wide set of values that go beyond narrow deﬁnitions of clinical utility.
Far from being limited to the individual sphere, the values of personal
genomic information are intrinsically social. People use their test results
to learn more about themselves and their connection to others, to think
about the future together with their family and friends, and/or to con-
tribute to research. Bringing broader notions of utility and value to the
debate on DTC testing is a necessary perspective to explain why people
use DTC testing. Moreover, it changes the point of gravity of these
debates, which so far have been focused on risks to test-takers, and on
data protection andprivacy. If health data are intrinsically social, privacy
needs to be seen as a collective (Tubaro et al., 2014) and a social con-
cern. Not only personal genomic data, but personal health data more
broadly often disclose information about more than one person, and
their production and use are embedded in social processes rather than
solipsistic ones. As argued above, if I download my health records I am
typically not merely doing this to “know myself” better. I am doing
this to address my healthcare with my family and with my doctors, to
be able to discuss my future and/or my concerns with my children or
my partner, or to download my data to enable further analyses to be
done by others. There is nothing exclusively individualistic about any
of these practices, at least no more individualistic than gardening,
cooking, or writing a book.
Yet privacy has also become a social concern because it has become a
fundamental interest of people in light of the strongpower asymmetries
that dominate the information age. In societies where powerful corpo-
rations, including governmental agencies, are ultimately in the service
of business interests, surveillance is no longer primarily a technology
of government but a technology of economic value creation
(Prainsack, in preparation). Because governments are too invested in
pursuing economic objectives to curtail the power of large private cor-
porations, the solution to the problem of surveillance (including DNA-
based surveillance) cannot come from the government. Governments
continue to issue and revise data-protection legislation, but they are
no longer willing or able to hit large corporations where it hurts.Solutions must thus also come from us, the citizens: from citizens who
resist surveillance from both “Big Brother and Company Man”, as Jerry
Kang et al. (2012); from citizens who demand to knowwhat kind of in-
formation is held about them in public and private repositories; and
from citizens who donate data to “information commons” that use
data strictly for public beneﬁt, instead of signing them over to those
who monitor us for their own proﬁt.
Acknowledgments
The authors are grateful to Simone Bateman, Dani Crocetti, Lorenzo
Del Savio, Klaus Hoeyer, Ilana Löwy, Federica Lucivero, and the Editor
of this Special Issue, Misha Angrist, and the anonymous reviewers for
their insightful and helpful comments on thismanuscript. The usual dis-
claimer applies. Part of the research leading to this contribution has re-
ceived funding from the People Programme (Marie Curie Actions) of the
European Union Seventh Framework Programme (FP7/2007–2013)
under REA grant agreement no. FP7-MC-IEF-331145.
References
Angrist, M., 2010. Here is a Human Being: At the Dawn of Personal Genomics.
HarperCollins, New York.
Bloss, C.S., Schork, N.J., Topol, E.J., 2011. Effect of direct-to-consumer genomewide proﬁl-
ing to assess disease risk. N. Engl. J. Med. 364 (6), 524–534.
Bloss, C.S., Wineinger, N.E., Darst, B.F., Schork, N.J., Topol, E.J., 2013. Impact of direct-to-
consumer genomic testing at long term follow-up. J. Med. Genet. 50 (6), 393–400.
Bloss, C.S., et al., 2010. Consumer perceptions of direct-to-consumer personalized geno-
mic risk assessments. Genetics in Medicine 12 (9), 556–566.
Caulﬁeld, T., McGuire, A.L., 2012. Direct-to-consumer genetic testing: perceptions, prob-
lems, and policy responses. Annu. Rev. Med. 63 (1), 23–33.
Cherkas, L.F., Harris, J.M., Levinson, E., Spector, T., Prainsack, B., 2010. A survey of UK pub-
lic interest in internet-based personal genome testing. PLoS One 5 (10), e13473.
Covolo, L., Rubinelli, S., Ceretti, E., Gelatti, U., 2015. Internet-based direct-to-consumer ge-
netic testing : a systematic review. J. Med. Internet Res. 17 (12), e279.
Dheensa, S., Fenwick, A., Lucassen, A., 2015. Is this knowledge mine and nobody else's? I
don't feel that.” Patient views about consent, conﬁdentiality and information-sharing
in genetic medicine. J. Med. Ethics http://dx.doi.org/10.1136/medethics-2015-
102781 (online ﬁrst).
Dickenson, D., 2013. Me Medicine vs. We Medicine: Reclaiming Biotechnology for the
Common Good. Columbia University Press, New York and Chichester, UK.
Doe, J., 2014. With genetic testing, I gave my parents the gift of divorce. Vox Genet. (9
September, Available at: http://www.vox.com/2014/9/9/5975653/with-genetic-
testing-i-gave-my-parents-the-gift-of-divorce-23andme).
Ducournau, P., Beaudevin, C., 2011. Génétique En Ligne. Déterritorialisation Des Régula-
tions de Santé Publique et Formes de Développement Commercial. Anthropol.
Santé Rev. Int. Francoph. Anthropol. Santé 3, 1–18.
Ducournau, P., Gourraud, P.-A., Rial-Sebbag, E., Bulle, A., Cambon-Thomsen, A., 2011. Tests
Génétiques En Accès Libre Sur Internet. Méd. Sci. 27, 95–102.
Duncan, D.E., 2009. Experimental Man: What One Man's Body Reveals About His Future,
Your Health, and Your Toxic World. John Wiley & Sons, Hoboken, NJ.
Fishman, J.R., McGowan, M.L., 2014. “Will Personalized Medicine Transform Our Selves?”.
In: Werner-Felmayer, G., Schicktanz, S., Prainsack, B. (Eds.), Genetics as Social Prac-
tice: Transdisciplinary Views on Science and Culture. Ashgate Press, Farbham,
pp. 29–42.
Foster, M.W.,Mulvihill, J.J., Sharp, R.R., 2009. Evaluating the utility of personal genomic in-
formation. Genet. Med. 11 (8), 570–574.
Franck, L., 2011. My Beautiful Genome: Exposing Our Genetic Future, One Quirk at a Time.
Oneworld, Oxford, UK.
Grosse, S.D., Khoury, M.J., 2006. What is the clinical utility of genetic testing? Genet. Med.
8 (7), 448–450.
Harris, A., Kelly, S.E., Wyatt, S., 2014. Autobiologies on YouTube: narratives of direct-to-
consumer genetic testing. New Genet. Soc. 60–78.
Harris, A., Kelly, S.E., Wyatt, S., 2015. Autobiologies: making sense of engagements with
healthcare technologies. J. Med. Humanit. Soc. Stud. Sci. Technol. 7 (1–2).
Harris, A., Kelly, S.E., Wyatt, S., 2016. Cybergenetics. Health Genetics and New Media.
Routledge, London (in press).
Harvey, A., 2010. Genetic risks and healthy choices: creating citizen-consumers of genetic
services through empowerment and facilitation. Soc. Health Illness 32 (3), 365–381.
Herper, M., 2015. In big shift, 23andMe will invent drugs using customers data. Forbes
(Mar 12, www.forbes.com/sites/matthewherper/2015/03/12/23andme-enters-the-
drug-business-just-as-apple-changes-it/).
Hughes, V., 2013. 23andYou: does that commercial DNA test you just bought violate
somebody else's privacy? Medium. (4 December), Available at: https://medium.
com/matter/23-and-you-66e87553d22c#.gnlzh211f.
Hunter, D.J., Khoury, M.J., Drazen, J.M., 2008. Letting the genome out of the bottle: will we
get our wish? N. Engl. J. Med. 358 (2), 105–107.
Kang, J., Shilton, K., Estrin, D., Burke, J., Hansen, M., 2012. Self-surveillance privacy. Iowa
Law Rev. 97, 809–847.
8 M. Turrini, B. Prainsack / Applied & Translational Genomics 8 (2016) 4–8Khoury, M.J., 2003. Genetics and genomics in practice: the continuum from genetic dis-
ease to genetic information in health and disease. Genet. Med. 5 (4), 261–268.
Laurie, G.T., 2001. Challengingmedical–legal norms: the role of autonomy, conﬁdentiality,
and privacy in protecting individual and familial group rights in genetic information.
J. Legal Med. 22 (1), 1–54.
Leighton, J.W., Valverde, K., Bernhardt, B., 2012. The general public's understanding and
perception of direct-to-consumer genetic test results. Public Health Genomics 15
(1), 11–21.
McBride, C.M., et al., 2009. Characteristics of users of online personalized genomic risk as-
sessments: implications for physician–patient interactions. Gen. Med. 11 (8),
582–587.
McGowan, M.L., Fishman, J.R., Lambrix, M.A., 2010. Personal genomics and individual
identities: motivations and moral imperatives of early users. New Genet. Soc. 29
(3), 261–290.
McGuire, A.L., Burke, W., 2008. An unwelcome side effect of direct-to-consumer. JAMA
300 (22), 13–15.
McGuire, A.L., Diaz, C.M., Wang, T., Hilsenbeck, S.G., 2009. Social networkers' attitudes to-
ward direct-to-consumer personal genome testing. Am. J. Bioeth. 9 (6–7), 3–10.
Ofﬁt, Kenneth, 2008. Genomic proﬁles for disease risk: predictive or premature? JAMA
299 (11), 1353–1355.
Petrone, J., 2014. For consumer GenoicsMarket, 2014 was a year of new features, new
players, and ‘Unmatched’ sales. GenomeWeb. 23 December, Available at: https://
www.genomeweb.com/microarrays-multiplexing/consumer-genomics-market-
2014-was-year-new-features-new-players-and.
Pinker, S. 2009. My genome, myself. New York Times Sunday Magazine, MM24.
Prainsack, B., 2011. The power of prediction: how personal genomics became a policy
challenge. Österr. Z. Polit. 40 (4), 401–415.
Prainsack, B., 2014a. The powers of participatory medicine. PLoS Biol. 12 (4), 31001837.
Prainsack, B., 2014b. Understanding participation: the ‘citizen Science’ of genetics. In:
Prainsack, B., Schicktanz, S., Werner-Felmayer, G. (Eds.), Genetics as Social Practice:
Transchiplinary Views on Science and Culture. Ashgate, Farnham, pp. 147–164.
Prainsack, B., Buyx, A., 2013. A solidarity-based approach to the governance of research
biobanks. Med. Law Rev. 21 (1), 71–91.Prainsack, Barbara, 2016. Personalization From Below: Participatory Medicine in the 21st
Century. New York University Press, New York (in preparation).
Savard, J., Mooney-Somers, J., Newson, A.J., Kerridge, I., 2014. Australians' knowledge and
perceptions of direct-to-consumer personal genome testing. Int. Med. J. 44 (1),
27–31.
Spector, T., Prainsack, B., 2013. Why the world keeps talking about 23andMe. Hufﬁngton
post (13 December). Available at: http://www.hufﬁngtonpost.com/tim-spector/
23andme_b_4417322.html.
Sterckx, S., Cockbain, J., Howard, H.C., Borry, P., 2013. “I prefer a child with…” designer
babies, another controversial patent in the arena of direct-to-consumer genomics.
Genet. Med. 15 (12), 923–924.
Su, Y., Howard, H.C., Borry, P., 2011. Users' motivations to purchase direct-to-consumer
genome-wide testing: an exploratory study of personal stories. J. Community
Genet. 2 (3), 135–146.
Taylor, M., 2012. Genetic Data and the Law: A Critical Perspective on Privacy Protection.
Cambridge University Press, Cambridge, UK.
Tubaro, P., Casilli, A., Sarabi, Y., 2014. Against the Hypothesis of the End of Privacy: An
Agent-based Modelling Approach to Social Media. Springer, Berlin.
Turrini, M., 2015. Practicing the biomedicine to come: direct-to-consumer genetic tests,
healthism and beyond. J. Med. Humanit. Soc. Stud. Sci. Technol. 7 (1–2).
Vayena, E., Gourna, E., Streuli, J., Hafen, E., Prainsack, B., 2012. Experiences of early users of
direct-to-consumer genomics in Switzerland: an exploratory study. Public Health
Genomics 15 (6), 352–362.
Vayena, E., Ineichen, C., Stoupka, E., Hafen, E., 2014. Playing a part in research? University
students' attitudes to direct-to-consumer genomics. Public Health Genomics 17 (3),
158–168.
Widdows, H., 2013. The Connected Self: The Ethics and Governance of the Genetic Indi-
vidual. Cambridge University Press, Cambridge, UK.
Wienroth, M., Rodrigues, E. (Eds.), 2015. Knowing New Biotechnologies: Social Aspects of
Technological Convergence. Routledge, London.
Wright, C.F., Gregory-Jones, S., 2010. Size of the direct-to-consumer genomic testing mar-
ket. Genet. Med. 12 (9), 594-594.
